Oregon Health Sciences University researchers find a genetic link between vascular disease and a common human herpes virus

November 23, 1999

Portland, Ore. -- For years, scientists have proposed a connection between a common herpes virus and vascular problems that occur in patients who have undergone an organ transplant or angioplasty procedure to clear clogged arteries. However, the reason behind this connection has remained a mystery. Now, researchers at Oregon Health Sciences University believe they have discovered a mechanism in the body responsible for this puzzling health problem. Their work will be published in the Nov. 24 issue of the journal Cell.

The research at OHSU centers on the human cytomegalovirus (CMV), a member of the herpes family, which has infected 50 to 85 percent of the adult population across the United States. The virus remains alive in the body for the rest of the carrier's life, but many hosts are unaware they are carriers. This is due to the fact that the virus normally remains dormant and does not cause major health problems unless a person has a suppressed immune system.

During the past 20 years, many studies have linked the virus to the development of atherosclerosis and other vascular diseases that occur in solid organ transplant recipients, or in patients who have undergone balloon angioplasty for clogged arteries.

A key part of these diseases involves the over-accumulation of smooth muscle cells in the artery wall, which can block blood flow in a vessel. CMV is often observed in these smooth muscle cells. Researchers at OHSU have uncovered evidence that a CMV gene called US28 stimulates the smooth muscle cells to migrate. Two proteins known as chemokines bind with US28 and direct the smooth muscle cells to areas of inflammation that may occur in atherosclerosis or vascular disease in transplant patients.

Dan Streblow, Ph.D., a postdoctoral fellow in microbiology and immunology at OHSU, is the principal author in the study along with co-authors Cecilia Soderberg, M.D., Ph.D., and Patsy Smith, M.S., in collaboration with Jeffery Vieira, Ph.D., at the University of Washington. Streblow calls the research a big step in understanding how viruses play a role in atherosclerosis. "It is quite rewarding to finally reveal a genetic link between CMV and vascular disease," said Streblow.

The senior author of the study, Jay Nelson, Ph.D., professor of molecular microbiology and immunology at OHSU, and director of OHSU's Vaccine and Gene Therapy Center, believes this work may provide hope for all patients at risk for vascular disease. "This work provides the smoking gun to explain the vast amount of correlative evidence linking CMV to the acceleration of vascular disease," said Nelson.

Portland-based Activated Cell Systems, L.L.C., which funded part of this project, believes that in the future this work could result in pharmaceuticals that block this process before it even starts.
-end-


Oregon Health & Science University

Related Atherosclerosis Articles from Brightsurf:

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

T cells can shift from helping to harming in atherosclerosis
At La Jolla Institute for Immunology (LJI) researchers are dedicated to finding a way to stop plaques from forming in the first place.

New nanoparticle drug combination for atherosclerosis
Physicochemical cargo-switching nanoparticles (CSNP) designed by KAIST can help significantly reduce cholesterol and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation.

Atherosclerosis -- How a microRNA protects vascular integrity
Ludwig-Maximilian-Universitaet (LMU) in Munich researchers have discovered a hitherto unknown molecular function of a specific microRNA that preserves integrity of the endothelium and reduces the risk of atherosclerosis.

Atherosclerosis progresses rapidly in healthy people from the age of 40
A CNIC study published in JACC demonstrates that atheroma plaques extend rapidly in the arteries of asymptomatic individuals aged between 40 and 50 years participating in the PESA-CNIC-Santander study.

Scaling up a nanoimmunotherapy for atherosclerosis through preclinical testing
By integrating translational imaging techniques with improvements to production methods, Tina Binderup and colleagues have scaled up a promising nanoimmunotherapy for atherosclerosis in mice, rabbits and pigs -- surmounting a major obstacle in nanomedicine.

Bladder drug linked to atherosclerosis in mice
A drug used in the treatment of overactive bladder can accelerate atheroclerosis in mice, researchers at Karolinska Institutet in Sweden report in a study published in the Proceedings of the National Academy of Sciences (PNAS).

A new therapeutic target for blocking early atherosclerosis in progeria
Researchers at the Centro Nacional de Investigaciones Cardiovasculares and the Universidad de Oviedo have discovered a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome.

Protective mechanism against atherosclerosis discovered
Immune cells promoting inflammation play a crucial role in the development of atherosclerosis.

Atherosclerosis: Stopped on time
For the first time, LMU researchers are pointing out the influence of the internal clock on atherosclerosis.

Read More: Atherosclerosis News and Atherosclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.